TargImmune Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A

TargImmune Therapeutics General Information

Description

Developer of molecule-based modality intended to assist in drug development to cure novel targeted cancer treatment. The company focuses on research, development, manufacture, exploitation, purchase, and sale of pharmaceutical and diagnostic products and technologies as well as focuses on the development of novel cancer-targeted technology that utilizes a non-viral vector to target and destroy cancer cells, enabling the healthcare sector to avail distinct drugs and treatments in the field of immuno-oncology and personalized therapy.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland
+41 061

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TargImmune Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 14-Mar-2025 Completed Pre-Clinical Trials
6. Later Stage VC 16-Jul-2021 Completed Pre-Clinical Trials
5. Early Stage VC 14-Jul-2020 Completed Pre-Clinical Trials
4. Grant 31-Oct-2019 Completed Pre-Clinical Trials
3. Early Stage VC 19-Jul-2019 Completed Pre-Clinical Trials
2. Early Stage VC 18-Jul-2017 $15.5M $17.6M Completed Startup
1. Early Stage VC 12-Sep-2016 $2.06M $2.06M Completed Startup
To view TargImmune Therapeutics’s complete valuation and funding history, request access »

TargImmune Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 2,000,000 $0.108840 $8.16 $8.16 1x $8.16 27.53%
Ordinary 400,000 $0.108840 $5.44 $5.44 1x $5.44 5.51%
To view TargImmune Therapeutics’s complete cap table history, request access »

TargImmune Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of molecule-based modality intended to assist in drug development to cure novel targeted cancer treatment. The
Drug Discovery
Basel, Switzerland
21 As of 2024

Basel, Switzerland
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TargImmune Therapeutics Competitors (15)

One of TargImmune Therapeutics’s 15 competitors is Anaveon, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anaveon Venture Capital-Backed Basel, Switzerland
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Virometix Venture Capital-Backed Schlieren, Switzerland
You’re viewing 5 of 15 competitors. Get the full list »

TargImmune Therapeutics Patents

TargImmune Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026229366-A1 Egfr-targeting vectors and therapeutics Pending 29-Apr-2025
WO-2026229365-A1 Low molecular weight polynucleotides and polyplexes comprising the same Pending 29-Apr-2025
WO-2025238236-A1 Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol Pending 16-May-2024
AU-2023376544-A1 Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol Pending 07-Nov-2022
EP-4615510-A1 Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol Pending 07-Nov-2022 A61K47/60
To view TargImmune Therapeutics’s complete patent history, request access »

TargImmune Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TargImmune Therapeutics Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
ENKORE International Enterprises Venture Capital Minority
European Commission Government
Genextra Venture Capital Minority
Pagani Ventures Venture Capital Minority
To view TargImmune Therapeutics’s complete investors history, request access »

TargImmune Therapeutics Investments (1)

TargImmune Therapeutics’s most recent deal was a Joint Venture with Race Immunotherapeutics. The deal was made on 10-Jul-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Race Immunotherapeutics 10-Jul-2017 Joint Venture Drug Discovery
To view TargImmune Therapeutics’s complete investments history, request access »

TargImmune Therapeutics FAQs

  • When was TargImmune Therapeutics founded?

    TargImmune Therapeutics was founded in 2016.

  • Where is TargImmune Therapeutics headquartered?

    TargImmune Therapeutics is headquartered in Basel, Switzerland.

  • What is the size of TargImmune Therapeutics?

    TargImmune Therapeutics has 21 total employees.

  • What industry is TargImmune Therapeutics in?

    TargImmune Therapeutics’s primary industry is Drug Discovery.

  • Is TargImmune Therapeutics a private or public company?

    TargImmune Therapeutics is a Private company.

  • What is TargImmune Therapeutics’s current revenue?

    The current revenue for TargImmune Therapeutics is .

  • How much funding has TargImmune Therapeutics raised over time?

    TargImmune Therapeutics has raised $49.2M.

  • Who are TargImmune Therapeutics’s investors?

    ENKORE International Enterprises, European Commission, Genextra, and Pagani Ventures have invested in TargImmune Therapeutics.

  • Who are TargImmune Therapeutics’s competitors?

    Anaveon, Genetix Biotherapeutics, Alaunos Therapeutics, Inovio Pharmaceuticals, and Virometix are some of the 15 competitors of TargImmune Therapeutics.

  • When was TargImmune Therapeutics acquired?

    TargImmune Therapeutics was acquired on 14-Mar-2025.

  • Who acquired TargImmune Therapeutics?

    TargImmune Therapeutics was acquired by iOncologi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process